Ratan Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Ratan Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30,000	Closed	-$1.41M	–	82
2021 Q3	$1.41M	Sell	30,000 -47,600	-61%	-$2.55M	0.18%	64
2021 Q2	$4.73M	Sell	77,600 -6,201	-7%	-$354K	0.41%	57
2021 Q1	$5.16M	Buy	83,801 +71,201	+565%	+$4.66M	0.57%	52
2020 Q4	$896K	Hold	12,600	–	–	0.1%	91
2020 Q3	$473K	Hold	12,600	–	–	0.07%	86
2020 Q2	$411K	Sell	12,600 -5,400	-30%	-$164K	0.14%	42
2020 Q1	$522K	Hold	18,000	–	–	0.24%	35
2019 Q4	$631K	Sell	18,000 -28,548	-61%	-$791K	0.38%	29
2019 Q3	$999K	Sell	46,548 -13,452	-22%	-$372K	0.53%	31
2019 Q2	$1.62M	Buy	+60,000	New	+$1.64M	0.36%	39

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ratan Capital Management's BBIO Position: Q4 2021 in Review

Ratan Capital Management sold out of BridgeBio Pharma (BBIO) in Q4 2021, closing a stake of 30,000 shares — an estimated $1.41M sold.

Ratan Capital Management first reported a position in BBIO in Q2 2019 and held it in 10 quarters. The position peaked at $5.16M in Q1 2021. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

Ratan Capital Management reported no remaining BridgeBio Pharma position as of Q4 2021 after selling out during the quarter.
Ratan Capital Management sold 30,000 BridgeBio Pharma shares in Q4 2021, an estimated $1.41M.
Ratan Capital Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 10 quarters.
Ratan Capital Management's BridgeBio Pharma position peaked at $5.16M in Q1 2021.
195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Ratan Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.